In an open‐label Phase Ib trial, gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate (ORR) with acceptable safety in women with hormone receptor‐positive, HER2(−) advanced breast cancer [163]. The gene discussed is ERBB2; the disease is breast carcinoma.